In particular, it is unclear whether CTLA-4 inhibition after progression on atezolizumab plus bevacizumab or other anti-VEGF plus anti-PD-(L)1 combinations have utility in HCC given that such regimens have been the preferred front-line treatments for eligible patients. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.